SCHEMBL1031377

SCHEMBL1031377

CC1CCC(Nc2ncc(-c3ccc(OCC#N)cc3)c(OC3CCOC3)n2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
GRM5 P41594 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
RAB9A P51151 1/20 0.35
HSD17B10 Q99714 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
STAT3 P40763 1/20 0.35
JAK3 P52333 1/20 0.35
FGFR4 P22455 1/20 0.35
MAPK1 P28482 4/20 0.34
MAPK10 P53779 2/20 0.34
MAPK8 P45983 2/20 0.33
MAPK9 P45984 2/20 0.33
FGFR3 P22607 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1334218 1.00 CNR1 (0.37) CNR1CNR2GRM5KDM4EALDH1A1
SCHEMBL1031371 1.00 CNR1 (0.37) CNR1CNR2GRM5KDM4EALDH1A1
SCHEMBL1031374 1.00 CNR1 (0.37) CNR1CNR2GRM5KDM4EALDH1A1
SCHEMBL1334221 1.00 CNR1 (0.37) CNR1CNR2GRM5KDM4EALDH1A1
SCHEMBL1332925 1.00 CNR1 (0.37) CNR1CNR2GRM5KDM4EALDH1A1
SCHEMBL1033651 0.96 JAK2 (0.37) GRM5KDM4EALDH1A1MAPTHPGD
SCHEMBL1033650 0.96 JAK2 (0.37) GRM5KDM4EALDH1A1MAPTHPGD
SCHEMBL1334189 0.95 MAPK8 (0.38) CNR1CNR2GRM5KDM4EALDH1A1
SCHEMBL1334187 0.95 MAPK8 (0.38) CNR1CNR2GRM5KDM4EALDH1A1
SCHEMBL1332899 0.89 GRM5 (0.39) GRM5KDM4EALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513242-B2 Pyrimidine compounds and methods of making and using same CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2013-08-20 US disclosed
US-20110281873-A1 Pyrimidine Compounds and Methods of Making and Using Same CYSTIC FIBROSIS FOUNDATION 2011-11-17 US disclosed
WO-2011008931-A2 ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2011-01-20 WO disclosed
WO-2010068863-A2 PYRIMIDINE COMPOUNDS AND METHODS OF MAKING AND USING SAME CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281873-A1 Pyrimidine Compounds and Methods of Making and Using Same CFTR, GPR17, TYMS CNR1 1055/4885CNR2 836/4885GRM5 2764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.